Amylin (AMLN) Reports Temp. Restraining Order Issued Against Lilly (LLY)
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) reports that the United States District Court for the Southern District of California issued a temporary restraining order against Eli Lilly and Company (NYSE: LLY) related to litigation with respect to the Amylin / Lilly diabetes collaboration agreement.
From the release: "The U.S. District Court restrained Lilly from proceeding with its plans to use the same sales force to sell both exenatide and Boehringer Ingelheim GmbH's competitive linagliptin. The court also enjoined Lilly from disclosing any confidential information about exenatide to any of its sales representatives or employees participating in the marketing, promotion or sale of linagliptin."
From the release: "The U.S. District Court restrained Lilly from proceeding with its plans to use the same sales force to sell both exenatide and Boehringer Ingelheim GmbH's competitive linagliptin. The court also enjoined Lilly from disclosing any confidential information about exenatide to any of its sales representatives or employees participating in the marketing, promotion or sale of linagliptin."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
